Antineoplaston Therapy in Treating Patients With Mantle Cell Lymphoma

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically proven stage II, III, or IV mantle cell lymphoma that is not curable by surgery, radiotherapy, and/or chemotherapy
• Measurable tumor of greater than 2 cm in largest diameter for lymph nodes located in head, neck, axillary, inguinal, and femoral areas (at least 1 cm for other areas)
• PATIENT CHARACTERISTICS:
• Age:
• 18 and over
• Performance status:
• Karnofsky 60-100%
• Life expectancy:
• At least 2 months
• Hematopoietic:
• WBC greater than 2000/mm\^3
• Platelet count greater than 20,000/mm\^3
• Hepatic:
• No hepatic insufficiency
• Bilirubin no greater than 2.5 mg/dL
• SGOT and SGPT no greater than 5 times upper limit of normal
• Renal:
• Creatinine no greater than 2.5 mg/dL
• No history of renal conditions that contraindicate high dosages of sodium
• Cardiovascular:
• No hypertension
• No history of congestive heart failure
• No history of cardiovascular conditions that contraindicate high dosages of sodium
• Other:
• Not pregnant or nursing
• Fertile patients must use effective contraception during and for 4 weeks after study participation
• No serious active infections requiring treatment
• PRIOR CONCURRENT THERAPY:
• Biologic therapy:
• At least 4 weeks since prior immunotherapy and recovered
• No concurrent immunomodulatory agent (e.g., interferon or interleukin-2)
• Chemotherapy:
• At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas) and recovered
• No concurrent antineoplastic agent
• Endocrine therapy:
• At least 4 weeks since prior corticosteroids (e.g., dexamethasone or prednisone)
• No concurrent dexamethasone, prednisone, or other corticosteroids
• Radiotherapy:
• At least 8 weeks since prior radiotherapy and recovered
• Surgery:
• Not specified
• Other:
• No prior antineoplaston therapy
• No concurrent antibiotics, antifungals, or antivirals